ReProtect (United States)

Recent papers from ReProtect (United States)

1. Increasing isotropy and predictability through electroplating of tensile properties of polyamide 12 parts manufactured by selective laser sinteringProgress in Additive Manufacturing · 2025
2. Skin immunisation activates an innate lymphoid cell-monocyte axis regulating CD8+ effector recruitment to mucosal tissuesNature Communications · 2019
3. Vaginal pH measured in vivo: lactobacilli determine pH and lactic acid concentrationBMC Microbiology · 2019
4. Comparison of the vaginal environment in rhesus and cynomolgus macaques pre‐ and post‐lactobacillus colonizationJournal of Medical Primatology · 2017
5. Pharmacokinetics and Preliminary Safety of Pod-Intravaginal Rings Delivering the Monoclonal Antibody VRC01-N for HIV Prophylaxis in a Macaque ModelAntimicrobial Agents and Chemotherapy · 2017
6. Biomarkers and biometric measures of adherence to use of ARV‐based vaginal ringsJournal of the International AIDS Society · 2016
7. Cell-Associated Transmission of HIV Type 1 and Other Lentiviruses in Small-Animal ModelsThe Journal of Infectious Diseases · 2014
8. An interdisciplinary framework for measuring and supporting adherence in HIV prevention trials of ARV‐based vaginal ringsJournal of the International AIDS Society · 2014
9. Vaginal pH and Microbicidal Lactic Acid When Lactobacilli Dominate the MicrobiotaPLoS ONE · 2013
10. Vaginal concentrations of lactic acid potently inactivate HIVJournal of Antimicrobial Chemotherapy · 2013
11. Appropriateness of Hydroxyethylcellulose Gel as a Placebo Control in Vaginal Microbicide TrialsJAIDS Journal of Acquired Immune Deficiency Syndromes · 2013
12. Non-Specific Microbicide Product Development: Then and NowCurrent HIV Research · 2012
13. Acceptability of Optical Coherence Tomography and Abstinence Requirements Among Women Participating in Microbicide Safety TrialsSexually Transmitted Diseases · 2011
14. SPL7013 Gel (VivaGel®) Retains Potent HIV-1 and HSV-2 Inhibitory Activity following Vaginal Administration in HumansPLoS ONE · 2011
15. Perceptions of Reimbursement for Clinical Trial ParticipationJournal of Empirical Research on Human Research Ethics · 2011
16. In vaginal fluid, bacteria associated with bacterial vaginosis can be suppressed with lactic acid but not hydrogen peroxideBMC Infectious Diseases · 2011
17. Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in womenAIDS · 2011
18. Cervicovaginal fluid and semen block the microbicidal activity of hydrogen peroxide produced by vaginal lactobacilliBMC Infectious Diseases · 2010
19. An acceptability and safety study of the Duet® cervical barrier and gel delivery system in ZimbabweJournal of the International AIDS Society · 2010
20. Formulating a Sulfonated Antiviral Dendrimer in a Vaginal Microbicidal Gel Having Dual Mechanisms of ActionDrug Development and Industrial Pharmacy · 2008